Showing results (141-150 of 268) with videos related to

Sort By:
Pageof 27
Medicina Clinica|January 13, 1990
[Evidence of HTLV-1 infection in different groups at risk in Barcelona]V Soriano, J Tor, A Ribera, et al.
Journal of Viral Hepatitis|May 12, 2010
Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patientsJ Medrano, S Resino, E Vispo, et al.
HIV Clinical Trials|February 11, 2009
Transient treatment exclusively containing nucleoside analogue reverse transcriptase inhibitors in highly antiretroviral-experienced patients preserves viral benefit when a fully active therapy was initiatedA Bonjoch, M J Buzon, J M Llibre, et al.
Medicina Clinica|January 28, 1995
[Tuberculosis in La Rioja from 1988 to 1993. Clinical course, localization, influence of human immunodeficiency virus infection, and sensitivity of mycobacterial tests]P Labarga Echeverría, M Perucha González, E Jiménez Gómez, et al.
AIDS (London, England)|August 26, 1998
Lack of evidence of a stable viral load set-point in early stage asymptomatic patients with chronic HIV-1 infectionC Vidal, F García, J Romeu, et al.
HIV Medicine|March 6, 2010
History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment changeJ Reekie, A Mocroft, B Ledergerber, et al.
The Journal of Infectious Diseases|April 16, 1998
Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patientsC Tural, J Romeu, G Sirera, et al.
AIDS (London, England)|April 19, 2000
Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppressionL Ruiz, J Martinez-Picado, J Romeu, et al.
Journal of Viral Hepatitis|September 15, 2011
Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitorsS Franco, R Bellido, E Aparicio, et al.
HIV Medicine|January 10, 2013
Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeksA M Mills, A Antinori, B Clotet, et al.
Pageof 27